Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19
Toxins · 2025
DOI: 10.3390/toxins17040160 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Toxins, 2025. Verfasst von Hye Sung Han und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong-si 14353, Republic of Korea. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, COVID-19, Neuromuscular Agents, Skin Aging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NUMECO Inc..
Abstract (Originalsprache)
MBA-P01 is a newly developed botulinum toxin A (BoNT-A) product designed to provide similar clinical effects as OnabotulinumtoxinA (ONA-BoNT-A), thereby providing an alternative treatment option for glabellar lines. It is another holotoxin preparation containing BoNT-A1. This randomized, double-blind, active-controlled, multi-center, Phase III clinical trial aimed to evaluate the efficacy and safety of MBA-P01 compared with OnabotulinumtoxinA (ONA-BoNT-A). In total, 318 participants were enrolled and received 20 units of MBA-P01 or ONA-BoNT-A on the forehead and glabella. At the 4-week assessment, the primary endpoint revealed no significant difference in the improvement rate of glabellar wrinkles between the two groups, confirming the non-inferiority of MBA-P01 to ONA-BoNT-A. Furthermore, some evaluation variables showed higher improvement rates for MBA-P01 than for ONA-BoNT-A. Adverse reactions and other safety analysis results were considered acceptable. Interestingly, a subgroup analysis of patients with the coronavirus disease (COVID-19) showed that the duration of BoNT-A treatment was shorter among those who contracted COVID-19 after BoNT-A treatment compared with those who have not. The limitations of this study include the predominance of female participants and the exclusive enrollment of Korean patients. MBA-P01 is expected to be clinically useful in terms of the efficient and safe reduction of glabellar wrinkles, which will provide patients with additional treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong-si 14353, Republic of Korea.
- Department of Dermatology, Chung-Ang University College of Medicine, Seoul 06974, Republic of Korea.
- Department of Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Republic of Korea.
- Department of Dermatology, Konkuk University School of Medicine, Seoul 05030, Republic of Korea.
- Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
- Medytox Inc., Seoul 06175, Republic of Korea.
ORCID-Profile: Hye Sung Han, Chong-Hyun Won, Wooshun Lee, Sun Young Choi
Förderung
- NUMECO Inc.
Zitieren
APA
Han, H. S., Kim, W. S., Lee, Y., Won, C. H., Lee, W., Choi, S. Y., & Kim, B. J. (2025). Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19. Toxins. https://doi.org/10.3390/toxins17040160
Vancouver
Han HS, Kim WS, Lee Y, Won CH, Lee W, Choi SY, et al. Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19. Toxins. 2025. doi:10.3390/toxins17040160
BibTeX
@article{Han2025,
author = {Han, Hye Sung and Kim, Won-Serk and Lee, Yangwon and Won, Chong-Hyun and Lee, Wooshun and Choi, Sun Young and Kim, Beom Joon},
title = {Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19},
journal = {Toxins},
year = {2025},
doi = {10.3390/toxins17040160}
}
EUVIMED